kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
2,306.0
JPY
-79.5
(-3.33%)
Apr 28, 3:30 pm JST
14.48
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
2,290
Apr 28, 11:59 pm JST
Summary Chart Historical News Financial Result
PER
13.7
PBR
2.26
Yield
3.47%
Margin Trading Ratio
30.74
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
2,385.5 JPY 14.96 USD
Previous Close Apr 27
2,385.5 JPY 14.96 USD
High Apr 28, 9:00 am
2,403.0 JPY 15.08 USD
Low Apr 28, 9:11 am
2,263.5 JPY 14.20 USD
Volume
10,866,600
Trading Value
0.03T JPY 0.16B USD
VWAP
2313.79 JPY 14.53 USD
Minimum Trading Value
230,600 JPY 1,448 USD
Market Cap
4.17T JPY 0.03T USD
Number of Trades
15,883
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
6,878
1-Year High Feb 5, 2026
25,789
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 581,600 686,900 1.18
Apr 17, 2026 586,600 593,900 1.01
Apr 10, 2026 625,600 533,300 0.85
Apr 3, 2026 679,400 602,600 0.89
Mar 27, 2026 1,283,400 591,500 0.46
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.